News | Breast Biopsy Systems | July 07, 2021

Serena Bright sets new standards for breast cancer detection and biopsy technology

Serena Bright sets new standards for breast cancer detection and biopsy technology

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around the United States. Serena Bright is the industry’s first contrast-guided biopsy solution, helping empower clinicians and patients in their fight against breast cancer. The technology, which received U.S. Food and Drug Administration 510(k) clearance in May 2020, allows patients to have their breast biopsy exams with contrast guidance using the same mammography equipment, in the same room, and with the same staff as the screening or diagnostic mammogram.

Among others, Serena Bright has been installed at Thomas Jefferson University Hospital (Philadelphia, Pa.), Boca Raton Regional Hospital (Boca Raton, Fla.), HCA Blake Medical Center in (Bradenton, Fla.) and Lake Medical Imaging & Breast Center (The Villages, Fla.). Health systems worldwide are implementing the Serena Bright technology in their efforts against breast cancer, with hundreds of patients already seeing results from installations across the globe.

Serena Bright provides reliable and accurate results that lead to a clear path of action, usually without further testing. In the past, clinicians have typically needed to use other imaging guidance, such as MRI, for biopsy procedures for lesions found with contrast-enhanced mammography and not seen on ultrasound. Following an abnormal mammogram, it can take several weeks to get an MRI biopsy.[1] Now as the backlog of cancer screenings caused by COVID-19 persists, delays in diagnosis are leading to some presentations at more advanced stages and poorer clinical outcomes, with one study pointing to a potential increase of 33,890 excessive cancer deaths in the U.S. alone.[2]

Serena Bright may help decrease these delays, allowing follow-up biopsy procedures to be done in a matter of days, rather than waiting several weeks for an MRI biopsy. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast-Enhanced biopsy include shortened procedure time and improved overall patient experience.[3],[4]

“Especially in today’s world, as we start to regain a sense of normalcy post-pandemic, accurately identifying and confirming the extent of disease for patients is essential to getting them on the right path to a cure,” Jason Shames, M.D., Associate Director of Research, Division of Breast Imaging, Co-Director, Breast Imaging Fellowship at Thomas Jefferson University Hospital, said. “With Serena and Serena Bright, we are now able to provide our patients and treatment teams with more confident locoregional staging results in a more accelerated, cost effective way.”

Critical to this technology’s application is GE Healthcare’s SenoBright HD Contrast-Enhanced Spectral Mammography (CESM), a diagnostic breast exam with iodine-based contrast that provides high sensitivity for more accurate breast cancer diagnosis.[5] By highlighting areas of unusual blood flow to localize lesions that need to be biopsied, CESM biopsy – Serena Bright – provides excellent image quality to help improve clinical confidence.

“Now more than ever, we need to give patients answers as fast as possible while also ensuring their comfort. We are proud to bring Serena Bright to our customers during this time when clarity and results are needed more rapidly,” said Agnes Berzsenyi, President and CEO of Women’s Health and X-Ray at GE Healthcare. “We’re optimistic about the potential for this technology to significantly improve breast cancer outcomes for women.”

For more information:  www.gehealthcare.com/products/mammography/serena-bright

 

 

[1] Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E. Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile. Journal of the National Comprehensive Cancer Network : JNCCN. 2018;16(12):1451-1457.

[2] Lai A, Pasea L, Banerjee  A,  et al . Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency.  medRxiv. Preprint posted online June 1, 2020. doi:10.13140/RG.2.2.34254.82242

[3] Data on file 2020 GE Healthcare; From first to last image.

[4] Accessed on 10/16/2020:  https://www.cedars-sinai.edu/Patients/Programs-and-Services/Imaging-Center/For-Patients/Exams-by-Procedure/MRI/MR-Guided-Breast-Biopsy/MR-Guided-Breast-Needle-Core-Biopsy-Procedure-Information.aspx

[5] Daniauxet al. Arch Gynecol Obstet , 2015

Related Content

News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Radiology Business

October 8, 2021 — Commonwealth Radiology Associates (CRA) is the largest private practice radiology group in ...

Time October 08, 2021
arrow
News | Enterprise Imaging

October 8, 2021 — HealthLevel, Inc., innovator of Foundations, a business operations analytics platform for healthcare ...

Time October 08, 2021
arrow
News | MRI Breast

October 7, 2021 — An automated system that uses artificial intelligence (AI) can quickly and accurately sift through ...

Time October 07, 2021
arrow
News | RSNA

October 7, 2021 — The Radiological Society of North America (RSNA) announced a slate of programming promoting health ...

Time October 07, 2021
arrow
News | Radiology Imaging

October 6, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), liver stiffness measurements (LSM) ...

Time October 06, 2021
arrow
News | Information Technology

October 6, 2021 — Fujifilm Medical Systems U.S.A., Inc. and Fujifilm Healthcare Americas Corporation (formerly Hitachi ...

Time October 06, 2021
arrow
News | Women's Health

October 6, 2021 — A commentary by Mayo Clinic Cancer Center researchers published in the Journal of Clinical Oncology ...

Time October 06, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
Subscribe Now